COVID-19 Project Team: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 47: Line 47:
*'''[[User:Farima Kahe|Farima Kahe, M.D.]]'''
*'''[[User:Farima Kahe|Farima Kahe, M.D.]]'''
*[[Tayyaba Ali, MD|Tayyaba Ali, M.D.]]
*[[Tayyaba Ali, MD|Tayyaba Ali, M.D.]]
*  [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]]


'''Hematologic disorders of COVID-19 Team Members'''
'''Hematologic disorders of COVID-19 Team Members'''

Revision as of 02:53, 19 June 2020

COVID-19 Project
Introduction
Team
Meetings' Summary
Topics
Ongoing Clinical Trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Meet The Team

Associate Editor(s)-in-Chief:

  • The name of the leaders are written in bold:

Cardiovascular Disorders of COVID-19 Team Members

Dermatologic Disorders of COVID-19 Team Members

Frequently Asked Inpatient Questions Team Members

Frequently Asked Outpatient Questions Team Members

Gastrointestinal disorders and of COVID-19

Hematologic disorders of COVID-19 Team Members

Nephrologic Disorders of COVID-19 Team Members

Neurologic Disorders and COVID-19 Team Members

Ongoing Clinical Trials of COVID-19 Team Members

Pediatrics and COVID-19

Pulmonary Disorders and COVID-19 Team Members